yahoo_financeOriginal article
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program
RegulatoryPositive
AI Analysis
Summary
OS Therapies has accepted a new FDA meeting request to review biomarker data as part of the FDA's BEST (Breakthrough Experiences and Successes with Therapies) Program. This represents regulatory engagement on biomarker strategy for the company.
Outcome Details
FDA meeting request accepted to review biomarker data as part of BEST Program
Importance:5/10
Sentiment:
0.30
FDABEST Programbiomarkerregulatory engagementmeeting request
Related Companies
Read the original article
Published by yahoo_finance on July 8, 2026 1:00 PM